Drug Type Small molecule drug |
Synonyms Albumin-bound docetaxel, Nab-docetaxel, ABI-008 + [4] |
Target |
Mechanism Tubulin inhibitors, Tubulin polymerisation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 15 Mar 2024 | |
stomach adenocarcinoma | Phase 3 | CN | 15 Mar 2024 | |
HER2 Positive Breast Cancer | Phase 3 | - | 01 Jul 2023 | |
c-Met positive non-small cell lung cancer | Phase 2 | CN | 02 Jul 2024 | |
Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 01 Dec 2023 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 27 Nov 2023 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 27 Jun 2023 | |
Pancreatic Cancer | Phase 2 | CN | 26 Dec 2022 | |
Recurrent ovarian cancer | Phase 2 | CN | 18 Aug 2022 | |
Metastatic breast cancer | Phase 2 | US | 01 Nov 2007 |
Phase 2 | 125 | HB1801 (albumin-bound docetaxel) | iiumxcnkrn(teyvopqmie) = fkwgtnowbi kjioxfcizd (bjsulwcbho, 42.15 - 72.34) View more | Positive | 24 May 2024 | ||
Docetaxel (Taxotere) | iiumxcnkrn(teyvopqmie) = lfevbkafyd kjioxfcizd (bjsulwcbho, 32.11 - 61.92) View more |